Intrathecal catheter and port placement for nusinersen infusion in children with spinal muscular atrophy and spinal fusion

xlomafota13 shared this article with you from Inoreader Intrathecal catheter and port placement for nusinersen infusion in children with spinal muscular atrophy and spinal fusion Via leak of cerebrospinal fluid Pediatr Radiol. 2021 Jul 12. doi: 10.1007/s00247-021-05126-4. Online ahead of print. ABSTRACT BACKGROUND: Spinal administration of medications is challenging in patients with complete posterior spinal fusion. We describe percutaneous image-guided intrathecal port placement for administration of the antisense oligonucleotide nusinersen for children and young adults with spinal muscular atrophy. OBJECTIVE: To describe and present our initial experience with a new technique for administering nusinersen in patients with spinal muscular atrophy and posterior spinal fusion. MATERIALS AND METHODS: We reviewed medical records of 13 patients who received intrathecal ports using DynaCT, biplane fluoroscopy and iGuide from April 2018 through June 2019, and we describe the clinical course over 1 year. RESULTS: Image-guided catheter and port implantation was successful in all cases. Two ports were subsequently removed, one for persistent cerebrospinal fluid leak and one for superficial infection. The other 11 have functioned successfully for a minimum of 23 months. CONCLUSION: We report our experience with image-guided intrathecal port placement in children with complete posterior spine fusion. The implanted port permits dosing in an outpatient setting and avoids the need for multiple future radiologic procedures, and it reduces discomfort, procedural costs and potential risks and sequelae of multiple anesthetics and radiation exposures. Further studies are needed to define the relative risks and benefits of intrathecal ports compared to other approaches such as repeated transforaminal lumbar punctures. PMID:34254153 | DOI:10.1007/s00247-021-05126-4 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.